The Role and Efficacy of Vitamin C in Sepsis: A Systematic Review and Meta-Analysis

Marwah Muhammad 1, Ahmad Jahangir 2, Ali Kassem 3, Saud Bin Abdul Sattar 3, Abdullah Jahangir 3, Syeda Sahra 3,*, Muhammad Rafay Khan Niazi 3, Ahmad Mustafa 3, Zeeshan Zia 3, Fasih Sami Siddiqui 3, Waled Sadiq 3, Danil Mishiyev 3, Aleena Sammar 4, Loai Dahabra 3, Aazib Irshad 5, Dany Elsayegh 3 and Michel Chalhoub 3

1 Sahiwal Medical College, Sahiwal 57000, Pakistan; mmarwah02@gmail.com
2 Mayo Hospital, Lahore 54000, Pakistan; ahmadjahangir786@gmail.com
3 Staten Island University Hospital, Northwell Health, Staten Island, New York, NY 10305, USA; akassem@northwell.edu (A.K.); ssattar1@northwell.edu (S.B.A.S.); abdullahjahangir6103@gmail.com (A.J.); mniazi@northwell.edu (M.R.K.N.); amustafa@northwell.edu (A.M.); zzia@northwell.edu (Z.Z.); fsiddiqui9@northwell.edu (F.S.S.); wsadiq@northwell.edu (W.S.); dmishiyev@northwell.edu (D.M.); ldahabra@northwell.edu (L.D.); delsayegh@northwell.edu (D.E.); mchalhoub1@northwell.edu (M.C.)
4 Pakistan Institute of Medical Sciences, Islamabad 44000, Pakistan; aleenasammar@gmail.com
5 Jinnah Hospital, Lahore 54000, Pakistan; aazibi05@gmail.com

* Correspondence: syrabukhari@gmail.com

Highlights:

- Sepsis is a significant global healthcare burden and the leading cause of in-patient mortality.
- Our analysis showed that vitamin C adjunct therapy was linked to a significant decrease in mortality, duration of vasopressor used, and SOFA scores in septic patients.
- There is a further need for a large, randomized control trial to define a clearer role of vitamin C in the care of septic patients.

Abstract: Clinical rationale for study: Despite advancements in critical care, the mortality rate of sepsis remains high, with an overall poor prognosis. There is a complex pathophysiology of a lethal cascade of cytokines and inflammatory proteins underlying sepsis. The use of vitamin C can theoretically suppress the inflammatory cascade but remains a questionable practice due to a lack of conclusive evidence. Aims of the study: To appraise the therapeutic role of vitamin C in sepsis. Materials and methods: A systematic review was conducted on PubMed, Embase, and the Central Cochrane Registry. The study included randomized clinical trials (RCTs) with vitamin C as an intervention arm in the septic patient population. For continuous variables, the difference in means (MD) and for discrete variables, the odds ratio (OR) was used. For effect sizes, a confidence interval of 95% was used. A \( p \)-value of less than 0.05 was used for statistical significance. The analysis was performed using a random-effects model irrespective of heterogeneity. Heterogeneity was evaluated using the \( I^2 \) statistic. Results: 23 studies were included with the total sample size of 2712 patients. In patients treated with vitamin C, there was a statistically significant reduction in the mortality: OR = 0.778 (0.635 to 0.954), \( p = 0.016 \); the sequential organ failure assessment score (SOFA): MD = −0.749 (−1.115 to −0.383), \( p < 0.001 \); and the duration of vasopressor requirement: MD = −1.034 days (−1.622 to −0.445), \( p = 0.001 \). No significant difference was found in the hospital or ICU length of stay. Conclusions and clinical implications: Vitamin C treatment regimens were associated with reduced mortality, SOFA score, and vasopressor requirement compared to the control in sepsis. Given its low cost and minimal adverse effects, we strongly encourage further large, randomized trials to establish vitamin C as a standard of care in sepsis management.

Keywords: sepsis; septic shock; ICU length of stay; hospital length of stay; vitamin C; ascorbic acid
1. Introduction

Sepsis is a syndrome characterized by a host's amplified dysregulated immune response to an underlying infection, leading to multi-organ malfunction. Despite advanced antimicrobials and therapeutics, sepsis has been linked with high mortality and morbidity [1]. Endotoxins such as lipopolysaccharide (LPS component of the cell membranes of Gram-negative bacteria) and other pathogen products can provoke the macrophages to secrete proinflammatory cytokines. This overwhelming immune response from the cytokines, including interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-1β (IL-1β), macrophage inflammatory protein-1β, and tumor necrosis factor (TNF-α) leads to sequelae of sepsis via capillary leakage and organ failure [2,3].

Globally and nationally, sepsis carries a major burden in morbidity and mortality on the health care system [4,5]. For instance, in 2017, approximately 11 million patients died due to sepsis. Fortunately, the incidence and mortality related to sepsis have decreased. In 1990, approximately 60.2 million sepsis cases were reported compared to 48.9 million cases in 2017. In the United States, sepsis is still the most common cause of death in hospitalized patients. Additionally, sepsis costs the health care system up to 24 billion dollars [6].

Ascorbic acid, more commonly known as vitamin C, is a vital trace element for the human body. Vitamin C is one of the most efficacious water-soluble antioxidants. The human body cannot form vitamin C, an essential nutritional element, and must be supplemented nutritionally. The role of vitamin C in treating multiple diseases has been significant due to its potent antioxidative properties [7]. The low cost of vitamin C, easy availability, and relatively safe side effect profile make it an attractive prospect as an adjunct to sepsis management.

Clinical Rationale for the Study

Multiple trials have been conducted showing the effectiveness of vitamin C in patients needing intensive care in combination with other drugs or alone. Multiple meta-analyses have reported variable outcomes with conflicting results. We performed this meta-analysis to pool the data from all the previous prospective, randomized control trials to increase the sample size and statistical power to evaluate the role of vitamin C in sepsis.

2. Materials and Methods

The study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

2.1. Eligibility Criteria

The studies that were included:

1. were RCTs with supraphysiologic doses of vitamin C as an intervention in septic patients with the standard of care as the control arm.
2. had patients aged > 18 years.
3. were available in the English language regardless of date or status of publications.

Studies that did not meet the above criteria were excluded.

2.2. Information Sources

The Central Cochrane Registry of clinical trials, Embase, and the PubMed database were used to search relevant articles. A MeSH search with keywords was performed in PubMed, and the PICO search tool was used to search Embase. The MeSH terms included “vitamin C” or “ascorbic” or “ascorbate” and “sepsis” or “septic” or “shock.” All the search terms were exploded without any limitations. The included articles were studied to identify any missing studies. The deadline for publication was set as 31 January 2022.
2.3. Trial Selection and Evaluation

Three authors independently and objectively reviewed all studies and excluded unqualifying articles. The risk of bias for the selected studies was calculated using the Cochrane collaborative tool and categorized into low, uncertain, and high.

The quality of evidence was graded using the GRADE system [8]. Each outcome was rated for quality, reducing the level of evidence for risk of bias, inconsistency, indirectness, and imprecision.

2.4. Data Extraction

Information was obtained using a pre-specified extraction table. Information was retrieved from the published trials and their tables/appendices, and a second author reviewed the information collected to ensure accuracy. The extracted data included the number of patients, mortality, sequential organ failure assessment score (SOFA) score, hospital length of stay, intensive care unit (ICU) length of stay, and days on pressors.

The primary outcome assessed was short-term mortality, and other outcomes included change in SOFA score, ICU length of stay, duration of vasopressor requirement, and hospital length of stay.

2.5. Statistical Analysis

The meta-analysis was performed using the Comprehensive Meta-analysis Software Version 3 (Biostat USA). We calculated the mean difference in continuous variables for treatment effect measurement while the odds ratio was calculated for discrete variables. Where medians and interquartile ranges were reported, they were assessed for skewness and whether the data were similar to a normal distribution, and the mean and standard deviation were imputed [9–11]. Standard errors were calculated using a 95% confidence interval, and a p-value of 0.05 was used to determine statistical significance. The analysis was performed using a random-effects model for consistency in analysis irrespective of heterogeneity. Heterogeneity was evaluated using the I^2 statistic; heterogeneity less than 40 was considered low, 40–60 moderate, and above 60 as high [8].

3. Results

3.1. Literature Search

A total of 2176 articles were identified in the initial search. After the removal of duplicates, 1930 articles were filtered. The first screening excluded 1858 articles. Full texts of 72 were analyzed. Nine articles were excluded due to being retrospective studies; ten did not have a relevant patient population (burn, etc.), fourteen were review articles, fifteen did not have a relevant intervention, and data reports from one study were not retrieved. Twenty-three randomized control trials were included, with a total of 2712 patients (Figure 1). The main characteristics are given in Table 1.
Table 1. Baseline characteristics of included studies.

| Study Name          | No. of Patients | Type of Therapy | Inclusion Criteria                                                                 | Exclusion Criteria                                                                 | Primary Outcome                                      | Secondary Outcome                                                                 |
|---------------------|-----------------|-----------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------|-----------------------------------------------------------------------------------|
| Rosengrave, 2022 [12] | 40              | Monotherapy     | Receiving intravenous antimicrobial therapy specifically for infection, receiving ≥ 5 µg/min noradrenaline or adrenaline, SOFA score ≥ 2 | Age < 18 years, consent could not be obtained, patient not expected to survive 24 h, known G6PD deficiency, known or suspected, pregnancy or breastfeeding. | Vasopressor requirement                              | ICU mortality, time to lactate clearance, need for renal replacement therapy (RRT), changes in severity-of-disease index scores, and duration of ICU and hospital stay |
| Wacker, 2022 [13]   | 124             | Monotherapy     | Adult patients within 24 h of onset of septic shock                               | Inability to obtain written consent and initiate study drug within 24 h of eligibility, known history of nephrothiasis, and shock occurring immediately following cardiac arrest. | 28-day mortality                                     |                                                                                   |
| Lv, 2021 [14]       | 117             | Monotherapy     | Admitted to the ICU, age 18–75 years, meet criteria of sepsis, no vitamin C treatment before admission | Terminal-stage patients, pregnant or lactating females, long-term use of hormones or immunosuppressive agents, active malignancy, mental disorders, autoimmune diseases | 28-day mortality                                     | Changes in the SOFA scores in the first 72 h after ICU admission, application time of vasoactive drugs, duration of time in ICU, procalcitonin clearance |
| Mahmoodpoor, Jun 2021 [15] | 80              | Monotherapy     | Patients with severe pneumonia                                                    | Age 18–80 years, renal insufficiency, history of vitamin C usage during past 48 h, pregnancy or breastfeeding, life expectancy of fewer than 24 h, G6PD deficiency, DKA, nephrothiasis | Days on mechanical ventilation, vasopressor use and dose, 28-day mortality | CRP, procalcitonin, ICU length of stay (LOS)                                       |
| Fowler III, 2014 phase I [16] | 24              | Monotherapy     | Presence of a SIRS, suspected or proven infection, presence of sepsis-induced organ dysfunction | Terminal Cancer or Expected Survival < 24 h | Ascorbic acid safety and tolerability | Days on vasopressor, ventilator-free days, ICU length of stay, 28-day mortality |
| Fowler III, 2019 [17] | 167             | Monotherapy     | Should meet 2 of 4 SIRS criteria with the following: Mechanically ventilation, PaO2:FiO2 < 300 mm Hg, bilateral opacities by chest radiography within 1 week of known clinical insult, new or worsening respiratory symptoms without evidence of left atrial hypertension, suspected or proven infection | Age < 18 years, non-English speaking, >48 h had elapsed since they met ARDS criteria, pregnant or breastfeeding, not expected to survive 24 h, receiving home oxygen greater than 2 L/min: history of interstitial lung disease, DAH, DKA, nephrothiasis | Change in SOFA score from baseline to 96 h, change in plasma biomarkers of inflammation (CRP) and vascular injury (thrombomodulin levels) | All-cause 28-day mortality, ventilator-free days, ICU-free days, hospital-free days, SOFA score, vasopressor use, GCS, creatinine level |
| Study Name                  | No. of Patients | Type of Therapy | Inclusion Criteria                                                                                                                                                                                                 | Exclusion Criteria                                                                                                                                                                                                                      | Primary Outcome                                                                                     | Secondary Outcome                                                                                     |
|-----------------------------|-----------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| Zabet MH, 2016 [18]         | 28              | Monotherapy     | Patients with septic shock as per Surviving Sepsis Campaign and with the following criteria: Presence of SIRS with suspected or proven infection and presence of sepsis-induced organ dysfunction | Concomitant use of other antioxidants, corticosteroids administration, contraindication for high-dose ascorbic acid including bilateral ureteric obstruction, chronic hemodialysis, iron overload, oxalate stone formers, hemochromatosis, and glucose-6-phosphate dehydrogenase (G6PD) deficiency | Vasopressor dose and duration                                                                   | Duration of Intensive Care Unit (ICU) stay and 28-day mortality                                      |
| Nabil Habib, 2017 [19]      | 100             | Monotherapy     | Admitted with the diagnosis of Septic shock                                                                                                                                                                       | Pregnant and lactating females, history of oxalate nephrolithiasis, G6PD deficiency, PNH, hereditary hemochromatosis, shock not due to sepsis, or patients with mixed type of shock                                                                 | Need for organ supportive measures and Length of ICU stay | In-ICU mortality                                                                                     |
| Ferron-Celma, 2009 [20]     | 20              | Monotherapy     | Age > 18, meets sepsis criteria, undergoing abdominal surgery, POSSUM score > 30%                                                                                                                                   | Age < 18 years old, unable to obtain consent                                                                                                                  | Neutrophil apoptosis via Fas receptor expression and caspase-3, poly (ADP-ribose) polymerase (PARP), and Bcl-2 levels in neutrophils | Mortality                                                                                             |
| Galley, 1997 [21]           | 30              | Combination therapy | Meet septic shock criteria, receiving vasoconstrictor therapy (epinephrine, norepinephrine, dopamine)                                                                                                               | Age < 21 years old, unable to obtain consent                                                                                                           | Total lipid peroxidase, malondialdehyde, Arginine: Citrulline, total Nitrite, reactive redox iron, total antioxidant capacity | Mortality                                                                                             |
| Hussein, 2021 [22]          | 94              | Combination therapy | With septic shock on ICU admission or development during ICU stay                                                                                                                                                    | Pregnancy and lactation, contraindication to any of the components of the triple therapy regimen, G6PD deficiency, receiving another type of steroid during their stay, immunosuppressive medications, cancer patients, DNR/DNI patients | 28-day in-hospital mortality and ICU mortality                                                | Shock time and duration on pressors                                                                        |
| Wani, 2020 [23]             | 100             | Combination therapy | Admitted with a diagnosis of sepsis and septic shock with a serum lactate level of >2 mmol/L                                                                                                                               | Age < 18 years, Pregnancy                                                                                                                                  | In-hospital mortality                                                                                   | 30-day mortality, hospital LOS, duration of vasopressor therapy, lactate clearance, change in serum lactate, and the SOFA score over the first 4 days |
Table 1. Cont.

| Study Name         | No. of Patients | Type of Therapy          | Inclusion Criteria                                                                                           | Exclusion Criteria                                                                                           | Primary Outcome                                                                                      | Secondary Outcome                                                                                   |
|--------------------|-----------------|--------------------------|--------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| Sevransky, 2021    | 501             | Combination therapy      | Suspected or confirmed infection, ICU admission, acute respiratory and/or cardiovascular organ dysfunction attributed to sepsis and requiring vasopressor (regardless of agent or dose) | Age < 18 years old, cardiovascular or respiratory organ failure requiring treatment, life expectancy < 30 days, DNR/DNI and current hospitalization > 30 days at the time of randomization, allergies to intervention, primary hyperoxaluria, oxalate nephropathy, G6PD deficiency, pregnancy, or known active breastfeeding, incarceration | Number of ventilator and vasopressor-free days in the first 30 days following the day of randomization | 30-day mortality                                                                                     |
| Moskowitz, 2020    | 205             | Combination therapy      | Age > 18 years, with suspected or confirmed infection and were receiving a vasopressor because of sepsis     | Allergic to study drug components had a clinical indication for any of the study drugs, symptomatic kidney stones within the last year, G6PD deficiency, hemochromatosis, ESRD, or RRT, not expected to survive 24 h | Change in the (SOFA) score between enrollment and 72 h                                                   | Renal failure and 30-day mortality                                                                    |
| Mohamed, 2020      | 88              | Combination therapy      | Adult non-pregnant patients with septic shock with initiation inotropic/pressor support within 6 h of presentation | Patients with burns, limitations of care due to terminal illness, acute liver failure, pregnancy                  | Mortality during the inpatient stay                                                                     | Time to shock reversal, change in SOFA score over 72 h, need for mechanical ventilation, incidence of new-onset AKI and ICU/hospital LOS. |
| Iglesias, 2020     | 137             | Combination therapy      | Adults > 18 years of age with a primary diagnosis of sepsis or septic shock or diagnosis of sepsis or septic shock within 12 h of admission to the ICU | Age < 18, pregnancy, DNR/DNI, terminal end-stage disease, required immediate surgery, HIV positive with a CD4 < 50 mm³, G6PD deficiency, transferred from another hospital | Resolution of shock and change in SOFA score.                                                          | 28-day mortality, ICU mortality, hospital mortality, procalcitonin clearance, hospital LOS, ICU LOS, ventilator-free days. |
| Hwang, 2020        | 111             | Combination therapy      | Adult patients (19–89 years old) presented and were diagnosed with septic shock.                             | Transferred from another hospital with vasopressor administration or mechanical ventilator support, limitations to treatment due to terminal disease or DNR/DNI, receiving vitamin C or thiamine before enrolment, cardiac arrest before enrolment, renal or ureteral stones | The change in SOFA score between the time of admission and 72 h after admission                        | Shock reversal and 28-day mortality                                                                    |
Table 1. Cont.

| Study Name   | No. of Patients | Type of Therapy          | Inclusion Criteria                                                                 | Exclusion Criteria                                                                 | Primary Outcome                                                                 | Secondary Outcome                                                                 |
|--------------|----------------|--------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Fujii, 2020  | 216            | Combination therapy      | Diagnosed with septic shock within a maximum of 24 h before enrollment, vasopressor dependent for at least 2 h at the time of enrollment | Age < 18 years, DNR/DNI, imminent death, diagnosis of septic shock longer than 24 h ago, known or suspected disease with a strong indication or contraindication for any of the study drugs, another indication for hydrocortisone use other than septic shock. | Time alive and free of vasopressors at day 7 after randomization               | 28-day, 90-day, ICU, and hospital mortality, 28-day cumulative vasopressor free days, 28-day cumulative mechanical ventilation-free days, 28-day renal replacement therapy–free days, change in SOFA score at day 72 h, 28-day ICU-free days and hospital LOS |
| Chang P, 2020| 80             | Combination therapy      | Meeting the diagnostic criteria for sepsis, >18 years of age and procalcitonin > 2 ng/mL when entering the ICU | Pregnancy, terminal disease or DNR/DNI orders, major bleeding, cardiogenic shock, paraquat poisoning, persistent nonremovable infection sources. | 28-day all-cause mortality                                                      | Organ protection, procalcitonin reduction, adverse events related to therapy |
| Niu, 2019    | 234            | Monotherapy              | Age 18–75, meet diagnostic criteria for sepsis, no vitamin C used earlier in the hospitalization | Terminal-stage patients, pregnant or lactating females, long-term use of hormones or immunosuppressive agents, active malignancy, mental disorders | 28 Day mortality                                                               | 72 h change in SOFA, duration of vasopressors, elimination of Calcitonin, ICU length of stay |
| Beale, 2008  | 55             | Enteral pharma-co- nutrition supplement (Intestamin) | Age > 18 years old, meeting SIRS criteria and at least one organ dysfunction occurring within 24 h. of ICU admission, APACHE II score >10, expected LOS in the ICU > 3 days, and indication for enteral nutrition for > 5 days | Cardiogenic shock or severe congestive heart failure NYHA class IV), severe, Pre-existing, parenchymal liver disease with clinically significant portal hypertension (Childs C), COPD, chronic renal failure requiring dialysis, pregnancy, AIDS, Immunosuppression, active cancer treatment | SOFA score                                                                     | Mortality, length of stay and organ dysfunction |
| Study Name               | No. of Patients | Type of Therapy                              | Inclusion Criteria                                                                 | Exclusion Criteria                                                                                                                                                                                                 | Primary Outcome                      | Secondary Outcome                                                                 |
|-------------------------|----------------|----------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|-------------------------------------------------------------------------------------|
| Pontes-aruda, 2006 [33] | 103            | Continuously tube-fed with a diet enriched with Eicosapentaenoic acid, Gamma Linolenate, and antioxidants | Age > 18 years old with clinical diagnosis of severe sepsis or septic shock, requiring mechanical ventilation and enteral access. | Age < 18 years, significant limitation of survival prognosis and/or incurable disease, chronic renal insufficiency, acute pancreatitis without established origin, head trauma with a GCS score < 5, recent stroke or subarachnoid hemorrhage, immunologic suppression, no indication for enteral nutrition or imminence of receiving parenteral nutrition, receiving partial parenteral nutrition, presence of uncontrolled diarrhea, recent GIB, planned to wean from mechanical ventilation | 28-day mortality                  | Changes in oxygenation status, time receiving mechanical ventilation, period in the intensive care setting, and development of new organ dysfunctions. |
| Schneider 2011 [34]     | 58             | Enteral supplement Intestamin                | Age 18–75 years, sepsis, or SIRS (APACHE score 10–30), absence of severe gastrointestinal tract or metabolic diseases, enteral feeding within 48 h of admission with obtained written consent. | Expected patient survival less than 6 days, pregnancy or lactation, hemodynamically unstable, severe liver disease with cytolysis, gastrointestinal surgery in the last 4 weeks, severe enteritis/colitis, short intestine syndrome, GIB requiring intervention, and inability to enterally feed | ICU LOS                              | Hospital LOS, mortality, ventilator requirement and vasopressor requirement.        |
3.2. Risk of Bias

Allocation: Most studies provided details about the methodology of randomization, except one study [32].

Blinding: Most trials were double-blind, except for open-label studies [23,29].

Incomplete data outcomes: 20 studies were considered a low risk for incomplete data, and 3 were deemed an unclear risk [31–33].

Selective reporting: 2 studies were deemed an unclear risk for selective reporting [31,33], and one study did not provide reasons for excluding individuals from the analysis and was deemed at a high risk for bias [28].
The results of the risk of bias are shown in Figures 2 and 3. Overall, most of the information obtained from the studies was deemed to have a low to unclear risk of bias.

### 3.3. Publication Bias

The risk of publication bias was assessed using a funnel plot for mortality. No evidence of significant publication bias was detected (Figure 4).

### 3.4. Results of Quantitative Analysis

#### 3.4.1. Mortality

**Overall**

A total of 23 studies reported mortality with vitamin-C-containing therapies. Their use was associated with a statistically significant reduction in mortality with OR = 0.778 (0.635 to 0.954), \( p = 0.016 \), and \( I^2 = 25.688 \) (low heterogeneity, low certainty of evidence) (Figure 5).

![Figure 2. Summary of bias.](image-url)
3.3. Publication Bias

The risk of publication bias was assessed using a funnel plot for mortality. No evidence of significant publication bias was detected (Figure 4).

3.4. Results of Quantitative Analysis

3.4.1. Mortality

Overall

A total of 23 studies reported mortality with vitamin C-containing therapies. Their use was associated with a statistically significant reduction in mortality with $\text{OR} = 0.778$ (0.635 to 0.954), $p = 0.016$, and $I^2 = 25.688$ (low heterogeneity, low certainty of evidence) (Figure 5).

Intravenous Dosing

Twenty studies reported mortality with intravenous regimens containing vitamin C. Their use was associated with a statistically significant reduction in mortality; $\text{OR} = 0.780$ (628 to 0.968), $p = 0.024$, and $I^2 = 27.690$ (low heterogeneity, low certainty of evidence).

Enteral Dosing

Three studies reported mortality with enteral regimens containing vitamin C. Their use was not associated with a statistically significant change in mortality; $\text{OR} = 0.782$ (0.367 to 1.665), $p = 0.524$, and $I^2 = 36.416$ (low heterogeneity, very low certainty of evidence).
3.4.2. SOFA Score

Eleven studies reported a change in SOFA score with vitamin-C-containing treatment regimens. Their use was associated with a statistically significant reduction in SOFA score with MD = −0.749 (−1.115 to −0.383), \( p < 0.001 \), and \( I^2 = 25.862 \) (low heterogeneity, low certainty of evidence). (Figure 6).

### Overall Mortality

![Figure 5. Overall mortality.](image-url)

### SOFA Score

![Figure 6. SOFA score.](image-url)
3.4.3. Hospital Length of Stay
Six studies reported hospital length of stay with vitamin-C-containing treatment regimens. Their use was not associated with a significant reduction in hospital stay; MD = 1.321 (−1.073 to 3.714), p = 0.279, and I² = 20.95 (low heterogeneity, very low certainty of evidence).

3.4.4. ICU Length of Stay
Nine studies reported ICU length of stay with vitamin-C-containing treatment regimens. Their use was not associated with a significant decrease in ICU length of stay; MD = −0.804 days (−2.374 to 0.766), p = 0.315, I² = 52.347 (moderate heterogeneity, very low certainty of evidence).

3.4.5. Duration of Vasopressors Use
Twelve studies reported the duration of vasopressor support in patients with vitamin C therapy. Their use was associated with statistically significant reduced time on vasopressors; MD = −1.034 (−1.622 to −0.445), p = 0.001, I² = 88.966 (high heterogeneity, very low certainty of evidence).

3.5. Subgroup Analysis
3.5.1. Monotherapy
Treatment regimens with vitamin C monotherapy were associated with a statistically significant reduction in mortality: OR = 0.515 (0.390 to 0.680), p < 0.001, and I² = 0 (low heterogeneity, moderate certainty of evidence); a reduction in ICU length of stay: MD = −2.551 days (−4.577 to −0.525), p = 0.014, and I² = 37.983 (low heterogeneity); and a reduced time on vasopressors: MD = −1.180 days (−2.021 to −0.240), p = 0.006, and I² = 92.664 (high heterogeneity). No significant change in the length of hospital stay or SOFA scores was reported.

3.5.2. Combination Therapy
In some trials, vitamin C was used as a combination therapy with hydrocortisone and thiamine as an intravenous HAT regimen or enteral feed formula containing vitamin C. These combination regimens were associated with a statistically significant reduction in SOFA score: MD = −0.690 (−1.056 to −0.324), p < 0.001, and I² = 0 (low heterogeneity); and reduction in duration of vasopressor use: MD = −0.933 days (−1.341 to −0.525), p < 0.001, and I² = 17.709 (low heterogeneity). There was no statistical difference observed in mortality, ICU, or hospital length of stay.

3.6. Sensitivity Analysis
A sensitivity analysis for mortality was performed with the removal of studies identified with a possible high risk of bias, and no significant change in the results was noted: OR = 0.696 (0.538 to 0.900), p = 0.006 [23,26,29,34]. Similarly, studies with imputed standard deviations were excluded from SOFA score studies, but no significant change in the results was noted: MD = −1.062 (−1.458 to −0.666), p < 0.001 [13,24,29].

3.7. Summary of Results
Overall, treatment regimens containing vitamin C were associated with a statistically significant reduction in mortality, SOFA scores, and duration of vasopressor requirement compared to the control group. No statistically significant difference was found in ICU or hospital length of stay. A summary of the primary outcome (mortality) with the subgroup analysis results is shown in Table 2. A summary of the secondary outcomes is shown in Table 3.
### Table 2. Summary of results for the primary outcome (Mortality).

| Outcomes                                      | Relative Risk (95% CI) | Risk Difference (95% CI) | No. of Studies (Total Patients) | Certainty (GRADE) |
|-----------------------------------------------|------------------------|--------------------------|---------------------------------|-------------------|
| Overall Mortality                             | OR = 0.778 (0.635 to 0.954) | 32 deaths per 100 6 less deaths per 100 (1 fewer to 10 fewer) | 23 (2705)             | Low a |
| Mortality with IV Vitamin C regimens          | OR = 0.780 (628 to 0.968)  | 37 deaths per 100 6 less deaths per 100 (1 fewer to 10 fewer) | 20 (2489)             | Low b |
| Mortality with Enteral Vitamin C regimens     | OR = 0.782 (0.367 to 1.665) | 37 deaths per 100 5 less deaths per 100 (21 fewer to 10 more) | 3 (216)                | Very Low c |
| Mortality with Vitamin C Monotherapy         | OR = 0.515 (0.390 to 0.680) | 42 deaths per 100 15 fewer deaths per 100 (21 fewer to 9 fewer) | 10 (941)               | Moderate d |
| Mortality with Combination regimens containing Vitamin C | OR = 1.023 (0.836 to 1.251) | 34 deaths per 100 No significant difference (4 fewer to 5 more) | 13 (1764)              | Low e |

a Downgraded two levels for limitation in design (multiple routes of administration, doses, timing) and risk of bias.

b Downgraded two levels for design limitations (variable dosing and timing) and risk of bias.

c Downgraded three levels for imprecision (wide confidence intervals) and limitations in design (enteral feeding with variable dosing and absorption).

d Downgraded one level for design limitations (variable dosing and timing)

e Downgraded two levels for severe limitations in design (multiple concurrent interventions).

### Table 3. Summary of results (secondary outcomes).

| Outcomes                  | Number of Studies | Sample Size | Absolute Effect Size (95% CI) | Certainty (GRADE) |
|---------------------------|-------------------|-------------|--------------------------------|-------------------|
| SOFA Score                | 11                | 819         | 829                           | 0.75 lower (−1.12 lower to −0.38 lower) | Low a |
| Duration of vasopressor use | 9               | 449         | 449                           | 1.03 fewer days (1.62 fewer to 0.45 fewer) | Very Low b |
| Duration of vasopressor use | 9               | 449         | 449                           | 1.03 fewer days (1.62 fewer to 0.45 fewer) | Very Low b |
| ICU length of stay        | 12                | 333         | 333                           | 0.81 fewer days (1.64 fewer to 0.02 more) | Very Low c |
| Hospital length of stay   | 6                 | 239         | 239                           | 1.32 more days (1.07 fewer to 3.71 more) | Very Low d |

a Downgraded two levels for limitation in design (multiple routes of administration, doses, timing) and risk of bias.

b Downgraded three levels for inconsistency, limitation in design (multiple routes of administration, doses, timing), and risk of bias.

c Downgraded three levels for risk of bias, imprecision (wide confidence intervals), and limitations in design (variable dosing and timing).

d Downgraded three levels for risk of bias, imprecision (wide confidence intervals), and limitations in design (variable hospital protocols, drug dosing, and timing).

### 4. Discussion

This meta-analysis included only 23 randomized control trials, while retrospective studies were excluded from the analysis. In 20 of these studies, the studied group received intravenous treatment regimens containing vitamin C, while the other 3 studies included study groups that received enteral regimens containing vitamin C. Interventions in some of these selected studies included vitamin C alone (monotherapy group) and the standard of care. In other studies, vitamin C was combined with other treatments, including thiamine and hydrocortisone (combination therapy group). Interestingly, our results revealed that patients treated with the vitamin C had significantly improved outcomes across various measures compared with the standard of care, most importantly mortality: OR = 0.778 (0.635 to 0.954), \( p = 0.016 \). The exact physiological mechanism by which vitamin C exerts these effects is still not fully understood.

The role of free radicals and reactive oxygen species (ROS) has long been a subject of interest in explaining physiology and disease pathology. Halliwell et al. explored the role of free radicals and ROS in many medical arenas, including cancers and neurodegenerative diseases [35]. Ascorbic acid provides an electron to another molecule, after which it transforms into an ascorbyl radical, which is the oxidized form of ascorbic acid and a relatively stable free radical [36]. Ascorbic acid in sepsis has specifically gained more scientific attention in the past years. Outcomes including 28-day mortality, ICU and hospital length of stay, vasopressor requirements, changes in the SOFA score, and others were studied in various articles [22,26,36].

Ascorbic acid in septic patients reportedly decreases inflammatory markers (c-reactive protein and procalcitonin) [16]. Vitamin C possibly inhibits the TNF-a-induced phosphorylation of inhibitory kappa-B kinase (IKK kinase), suppressing NF-kB and histamine levels...
in the blood [37,38]. It may also suppress high mobility group box-1 (HMGB-1) release from the LPS-activated macrophages, leading to improved survival and reduced (HMGB-1) levels in the septic host [3,37–39].

High concentrations of vitamin C in macrophages, leukocytes, and lymphocytes enhance their phagocytic potential, oxidative killing, and promoting lymphocyte proliferation. The neutrophil extracellular trap (NET) is a novel mechanism deployed by the host cells to kill pathogens. Nevertheless, a disproportionate NET during sepsis can harm host organs, and vitamin C is shown to alter and mediate the NET formation during sepsis [40,41].

Studies have shown that adding vitamin C into a medium containing lymphocytes from the peripheral circulation reduces the lipopolysaccharide (LPS)-induced production of the proinflammatory cytokines, specifically TNF-α and IFN-γ [42], and increases the production of the anti-inflammatory cytokine IL-1 [42]. Similarly, other studies conducted in vitro show that mixing ascorbic acid with monocytes isolated from the peripheral circulation of patients with underlying pneumonia resulted in the diminished production of the proinflammatory cytokines TNF-α and IL-6 [43] and the augmentation of IFN levels [44–46]. Therefore, there is evidence that ascorbic acid influences cytokine regulation, including the modulation in the cytokine levels deranged in sepsis.

Several meta-analyses have analyzed the role of vitamin C in multiple diseases [47,48]; some studies have focused on critically ill patients [49,50], including heterogeneous diseases and patient populations in the analysis. In contrast, others have analyzed the role of vitamin C in specific patient populations, such as COVID-19 and respiratory tract infections [51,52]. Several studies have addressed the role of hydrocortisone, ascorbic acid, and thiamine in sepsis [53–57], while others have considered vitamin-C-containing regimens [27,58,59]. Some previous studies, which included all regimens containing vitamin C, have indicated a trend toward lower short-term mortality [47,58]. Studies including combination therapies have yielded heterogeneous results ranging from no difference in mortality [57] to significant changes in mortality [55]. Different inclusion parameters and study populations partially explain the heterogeneity of outcomes in different reviews. Based on conflicting data from multiple trials, “Surviving sepsis guidelines” recommended against routine use of intravenous vitamin C based on 7 RCTs included in their analysis. More studies with increasing data have been published since the publication of the guidelines.

Most of the previous meta-analyses have reported an improvement in SOFA scores with vitamin C use [54,57,60]. Since their publication, other trials have been performed. Our analysis adds to the growing evidence of the positive impact of vitamin C use in the septic patient population. Our study’s major strength is that it only included randomized trials and excluded all observational studies in order to generate the highest strength of evidence possible. We included all the latest literature on the topic to the best of our efforts. Our results demonstrating a reduction in mortality and SOFA score improvement align with most previous studies on the topic. In addition to the amelioration observed in the clinical status and significant improvement in patient care, this remains an important finding because intravenous vitamin C is readily available, very affordable, and has very limited secondary side effects.

This study, as a meta-analysis, remains a retrospective review and generates various biases. Heterogeneity remains a significant challenge, given the inclusion of studies with different patient populations in different stages of diseases. Secondly, there is no universally accepted dose of vitamin C, which could be defined as a “high dose,” and little to no data exist to guide frequency, dosing, and route of administration. Some of the studies utilized an enteral route of drug administration, which in the septic population suffers from erratic absorption and significant drug–drug interactions. Most studies did not report complete patient data, age groups, and reasons for mortality, which also weakens the overall certainty of the evidence. Many studies reported medians for reporting their outcomes, which showed significant deviation from the normal distribution and had to be excluded from the analysis, thereby decreasing the population pool [13,14,28,29,31]. Furthermore, the combination of intervention drugs with other drugs, differences in ICU
protocols, and hospital policies also contribute to the high heterogeneity and low certainty of the outcomes.

Overall, we made our greatest attempt to include all relevant published studies and extract data for analysis. There are several ongoing trials on this topic, and soon, we might have more definite answers regarding the efficacy, dosing, route, and timing of the administration of vitamin C in the septic patient population [61–63].

Clinical Implications and Future Directions

Based on this pooled evidence, we advocate using vitamin C as an adjunct to the standard of care for sepsis management, given the postulated reduction in mortality, low cost, and relatively safe adverse effect profile. There remains a need for a large, multi-center, randomized control trial with enough power to better understand and answer questions regarding the utility, timing of administration, route of delivery, and dosage of vitamin C in sepsis.

Author Contributions: Manuscript was written by A.K., M.M., S.B.A.S., A.J. (Abdullah Jahangir), A.J. (Ahmad Jahangir), L.D., M.R.K.N., A.S. and A.I. Data extraction and analysis by A.J. (Ahmad Jahangir), A.I., A.K., A.M. and Z.Z. Proofreading and literature review by A.J. (Abdullah Jahangir), D.M., F.S.S., W.S., S.S., D.E. and M.C. All authors have read and agreed to the published version of the manuscript.

Funding: This publication was prepared without any external source of funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Ethical approval was not necessary for the preparation of this article.

Data Availability Statement: Not applicable.

Conflicts of Interest: No conflict of interest are reported for all the authors.

References
1. Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.-D.; Coopersmith, C.M.; et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016, 315, 801–810. [CrossRef]
2. Tracey, K.J.; Fong, Y.; Hesse, D.G.; Manogue, K.R.; Lee, A.T.; Kuo, G.C.; Lowry, S.F.; Cerami, A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. *Nature* 1987, 330, 662–664. [CrossRef] [PubMed]
3. Ulloa, L.; Tracey, K.J. The “cytokine profile”: A code for sepsis. *Trends Mol. Med.* 2005, 11, 56–63. [CrossRef]
4. Adhikari, N.K.; Fowler, R.A.; Bhagwanjee, S.; Rubenfeld, G.D. Critical care and the global burden of critical illness in adults. *Lancet* 2010, 376, 1339–1346. [CrossRef]
5. Luhr, R.; Cao, Y.; Söderquist, B.; Cajander, S. Trends in sepsis mortality over time in randomised sepsis trials: A systematic literature review and meta-analysis of mortality in the control arm, 2002–2016. *Crit. Care* 2019, 23, 241. [CrossRef]
6. Rudd, K.E.; Johnson, S.C.; Agesa, K.M.; Shackelford, K.A.; Tsio, D.; Kivelan, D.R.; Colombara, D.V.; Ikuta, K.S.; Kissoon, N.; Finfer, S.; et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: Analysis for the Global Burden of Disease Study. *Lancet* 2020, 395, 200–211. [CrossRef]
7. Liu, Y.; Liu, C.; Li, J. Comparison of Vitamin C and its derivative antioxidant activity: Evaluated by using density functional theory. *ACS Omega* 2020, 5, 25467–25475. [CrossRef] [PubMed]
8. Guyatt, G.; Oxman, A.D.; Akl, E.A.; Kunz, R.; Vist, G.; Brozek, J.; Norris, S.; Falck-Ytter, Y.; Glasziou, P.; DeBeer, H.; et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J. Clin. Epidemiol.* 2011, 64, 383–394. [CrossRef]
9. Luo, D.; Wan, X.; Liu, J.; Tong, T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. *Stat. Methods Med. Res.* 2018, 27, 1785–1805. [CrossRef]
10. Wan, X.; Wang, W.; Liu, J.; Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med. Res. Methodol.* 2014, 14, 135. [CrossRef]
11. Shi, J.; Luo, D.; Wan, X.; Liu, Y.; Liu, J.; Bian, Z.; Tong, T. Detecting the skewness of data from the sample size and the five-number summary. *arXiv* 2020, arXiv:2010.05749.
12. Rosengrave, P.; Spencer, E.; Williman, J.; Mehrtens, J.; Morgan, S.; Doyle, T.; Van Der Heyden, K.; Morris, A.; Shaw, G.; Carr, A.C. Intravenous vitamin C administration to patients with septic shock: A pilot randomised controlled trial. *Crit. Care* 2022, 26, 26. [CrossRef] [PubMed]
34. Schneider, A.; Markowski, A.; Momma, M.; Seipt, C.; Luetting, B.; Hademi, J.; Wilhelmi, M.; Manns, M.P.; Wedemeyer, J. Tolerability and efficacy of a low-volume enteral supplement containing key nutrients in the critically ill. *Clin. Nutr.* 2011, 30, 599–603. [CrossRef] [PubMed]

35. Halliwell, B. Free radicals and antioxidants: Updating a personal view. *Nutr. Rev.* 2012, 70, 257–265. [CrossRef] [PubMed]

36. Michals, A.J.; Hagen, T.M.; Frei, B. Human genetic variation influences vitamin C homeostasis by altering vitamin C transport and antioxidant enzyme function. *Annu. Rev. Nutr.* 2013, 33, 45–70. [CrossRef] [PubMed]

37. Marik, P.E. Vitamin C for the treatment of sepsis: The scientific rationale. *Pharmacol. Ther.* 2018, 189, 63–70. [CrossRef]

38. Cárdeno, J.M.; Pedraza, A.; Bórquez-Ojeda, O.; Golde, D.W. Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. *Biochemistry 2002*, 41, 12995–13002. [CrossRef] [PubMed]

39. Wang, H.; Yang, H.; Czura, C.J.; Sama, A.E.; Tracey, K.J. HMGB1 as a late mediator of lethal systemic inflammation. *Am. J. Respir. Crit. Care Med.* 2001, 164, 1768–1773. [CrossRef] [PubMed]

40. Mohammed, B.M.; Fisher, B.J.; Kraskauskas, D.; Farkas, D.; Brophy, D.E.; Fowler, A.A.; Natarajan, R. Vitamin C: A novel regulator of neutrophil extracellular trap formation. *Nutrients* 2013, 5, 3131–3151. [CrossRef]

41. Hemiliä, H. Vitamin C and Infections. *Nutrients* 2017, 9, 339. [CrossRef]

42. Molina, N.; Morandi, A.C.; Bolin, A.P.; Otton, R. Comparative effect of fucoxanthin and vitamin C on oxidative and functional parameters of human lymphocytes. *Int. Immunopharmacol.* 2014, 22, 41–50. [CrossRef] [PubMed]

43. Chen, Y.; Luo, G.; Yuan, J.; Wang, Y.; Yang, X.; Wang, X.; Li, G.; Liu, Z.; Zhong, N. Vitamin C mitigates oxidative stress and tumor necrosis factor-alpha in severe community-acquired pneumonia and LPS-induced macrophages. *Mediat. Inflamm.* 2014, 2014, 426740. [CrossRef]

44. Dahl, H.; Degré, M. The effect of ascorbic acid on production of human interferon and the antiviral activity in vitro. *Acta. Pathol. Microbiol. Scand.* 1976, 84b, 280–284. [CrossRef]

45. Karpińska, T.; Kawecki, Z.; Kandefer-Szerszen, M. The influence of ultraviolet irradiation, L-ascorbic acid and calcium chloride on the induction of interferon in human embryo fibroblasts. *Arch. Immunol. Ther. Exp.* 1982, 30, 33–37.

46. Siegel, B.V. Enhancement of interferon production by poly(rI)-poly(rC) in mouse cell cultures by ascorbic acid. *Am. J. Respir. Crit. Care Med.* 2021, 201, 189–195. [CrossRef] [PubMed]

47. Ge, Z.; Huang, J.; Liu, Y.; Xiang, J.; Gao, Y.; Walline, J.H.; Lu, X.; Yu, S.; Zhao, L.; Li, Y. Thiamine combined with vitamin C in sepsis or septic shock: A systematic review and component network meta-analysis. *Sci. Rep.* 2020, 11, 12995–13002. [CrossRef] [PubMed]

48. Li, T.; Zeng, J.; Li, D.-H.; Yang, G.-Y.; Wang, K.; Deng, H.-F.; Jiang, H. Efficacy of intravenous vitamin C intervention for septic shock: A systematic review and meta-analysis based on randomized controlled trials. *Intensive Care Med.* 2022, 48, 16–24. [CrossRef] [PubMed]

49. Liu, Z.; Jiang, H.; Yang, G.-Y.; Wang, K.; Deng, H.-F.; Jiang, H. Efficacy of intravenous vitamin C intervention for septic patients: A systematic review and meta-analysis. *Intensive Care Med.* 2022, 48, e304–e312. [CrossRef] [PubMed]

50. Scholz, S.S.; Borgstedt, R.; Ebeling, N.; Menzel, L.C.; Jansen, G.; Rehberg, S. Mortality in septic patients treated with vitamin C: A systematic meta-analysis. *Crit. Care 2021*, 25, 17. [CrossRef] [PubMed]

51. Sato, R.; Hasegawa, D.; Prasitlumkum, N.; Ueoka, M.; Nishida, K.; Takahashi, K.; Nasu, M.; Dugar, S. Effect of IV High-Dose Vitamin C on Mortality in Patients with Sepsis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Croc Care Med.* 2021, 49, 2121–2130. [CrossRef] [PubMed]

52. Patel, J.J.; Ortiz-Reyes, A.; Dhalival, R.; Clarke, J.; Hill, A.; Stoppe, C.; Lee, Z.Y.; Heyland, D.K. IV Vitamin C in Critically Ill Patients: A Systematic Review and Meta-Analysis. *Crit. Care Med.* 2022, 50, e304–e312. [CrossRef] [PubMed]

53. Assouline, B.; Faivre, A.; Verissimo, T.; Sangla, F.; Berchtold, L.; Giraud, R.; Bendjelid, K.; Sgardello, S.; Elia, N.; Pugin, J.; et al. Thiamine, Ascorbic Acid, and Hydrocortisone as a Metabolic Resuscitation Cocktail in Sepsis: A Meta-analysis of Randomized Controlled Trials With Trial Sequential Analysis. *Crit. Care Med.* 2021, 49, 2112–2120. [CrossRef] [PubMed]

54. Wu, T.; Hu, C.; Huang, W.; Xu, Q.; Hu, B.; Li, J. Effect of Combined Hydrocortisone, Ascorbic Acid and Thiamine for Patients with Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. *Shock 2021*, 56, 880–889. [CrossRef]

55. Fong, K.M.; Au, S.Y.; Ng, G.W.Y. Steroid, ascorbic acid, and thiamine in adults with sepsis and septic shock: A systematic review and component network meta-analysis. *Sci. Rep. 2021*, 11, 15777. [CrossRef] [PubMed]

56. Ge, Z.; Huang, J.; Liu, Y.; Xiang, J.; Gao, Y.; Walline, J.H.; Lu, X.; Yu, S.; Zhao, L.; Li, Y. Thiamine combined with vitamin C in sepsis or septic shock: A systematic review and meta-analysis. *Eur. J. Emerg. Med.* 2021, 28, 189–195. [CrossRef] [PubMed]

57. Li, T.; Zeng, J.; Li, D.-H.; Yang, G.-Y.; Wang, K.; Deng, H.-F.; Jiang, H. Efficacy of intravenous vitamin C intervention for septic patients: A systematic review and meta-analysis based on randomized controlled trials. *Am. J. Emerg. Med.* 2021, 50, 245–252. [CrossRef]

58. Wei, X.-B.; Wang, Z.-H.; Liao, X.-L.; Guo, W.-X.; Wen, J.-Y.; Qin, T.-H.; Wang, S.-H. Efficacy of vitamin C in patients with sepsis: An updated meta-analysis. *Eur. J. Pharmacol.* 2020, 868, 172889. [CrossRef] [PubMed]

59. Wu, B.U.; Huang, J.Q.; Gardner, T.H.; Repas, K.; Delee, R.; Yu, S.; Smith, B.; Banks, P.A.; Conwell, D.L. Lactated Ringer’s solution reduces systemic inflammation compared with saline in patients with acute pancreatitis. *Clin. Gastroenterol. Hepatol.* 2011, 9, 710–717.e1. [CrossRef]
61. Hopkinson, D.A. High-Dose Intravenous Vitamin C as an Adjunctive Treatment for Sepsis in Rwanda. Available online: https://www.clinicaltrials.gov/ct2/show/NCT04088859?type=Intr&cond=vitamin+c&draw=3&rank=40 (accessed on 1 January 2022).

62. Kotanidou, A.; Vitamin, C. Hydrocortisone and Thiamine for Septic Shock (CORVICTES). University of Athens. Available online: https://www.clinicaltrials.gov/ct2/show/NCT03592693?type=Intr&cond=vitamin+c&draw=3&rank=41 (accessed on 1 January 2022).

63. Liu, Z. Clinical Efficacy of Megadose Vitamin C in Sepsis (CEMVIS). Zhujiang Hospital. Available online: https://www.clinicaltrials.gov/ct2/show/NCT05194189?rs=Without&type=Intr&cond=vitamin+c&draw=2&rank=16 (accessed on 1 January 2022).